Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (30300)	1/17/2000 10:13:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

In current edition of Worth magazine Jim McCamant comments about LGND...." over the next 6 to 12 months, Ligand will report results from numerous clinical trials and will file for up to three more approvals. In 2000, we expect it to join the elite group of biotechs that are actually profitable." He recommends LGND up to $16, so that one has already been taken out. His comments are found in the "What They're Buying" for February section of the magazine.